Dacomitinib (PF-00299804), an Irreversible Pan-Her Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-11-0730
Full Text
Open PDFAbstract
Available in full text
Date
July 3, 2012
Authors
Publisher
American Association for Cancer Research (AACR)